Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
4612
Millions of yen (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Financial Results PresentationFirst quarter of the fiscal year ending December 2026 (January–March)2 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥11,256 million
Operating profit¥3,244 million
Ordinary income¥3,043 million profit or loss before tax for the quarter
Net income¥1,793 million profit or loss for the quarter
Selling, general and administrative expenses¥3,570 million
Results for the three months of the current quarter
Revenue¥11,256 million
Operating profit (loss)¥3,244 million
Profit or loss before tax for the quarter¥3,043 million
Quarterly Profit and Loss¥1,793 million
Core operating profit or loss¥5,495 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in revenue¥4,612 millionFactors7 milestones were achieved in the first quarter, compared with 1 milestone in the same period of the previous year
- Decrease in R&D expenses¥-780 millionFactorsLower costs as multiple clinical development programs progressed, and a more focused approach to research and development areas
- Decrease in selling, general and administrative expenses¥-131 millionFactorsCost-cutting initiatives
New initiatives
- License agreement with Sunsera Pharmaceuticals Holdings for the development, manufacture and commercialization of vamorolone in Japan, South Korea, Australia and New Zealand
- Application for marketing approval for daridorexant in South Korea
- License agreement for a GPCR-targeting program with a European venture company and acquisition of shares in that company
- Changes to the directors
- Obtained marketing approval for QUVIVIQ in Taiwan, with a launch planned during 2026
| Item | Details |
|---|---|
| Document type | Financial Results Presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending December 2026 (January–March) |
| Net Sales | ¥11,256 million |
| Operating profit | ¥3,244 million |
| Ordinary income | ¥3,043 million (profit or loss before tax for the quarter) |
| Net income | ¥1,793 million (profit or loss for the quarter) |
| Selling, general and administrative expenses | ¥3,570 million |
| Results for the three months of the current quarter | Revenue ¥11,256 million / Operating profit (loss) ¥3,244 million / Profit or loss before tax for the quarter ¥3,043 million / Quarterly Profit and Loss ¥1,793 million / Core operating profit or loss ¥5,495 million |
| Breakdown of Factors Affecting the Change | Item Increase in revenue / Amount ¥4,612 million / Factors 7 milestones were achieved in the first quarter, compared with 1 milestone in the same period of the previous year, Item Decrease in R&D expenses / Amount ¥-780 million / Factors Lower costs as multiple clinical development programs progressed, and a more focused approach to research and development areas, Item Decrease in selling, general and administrative expenses / Amount ¥-131 million / Factors Cost-cutting initiatives |
| New initiatives | License agreement with Sunsera Pharmaceuticals Holdings for the development, manufacture and commercialization of vamorolone in Japan, South Korea, Australia and New Zealand, Application for marketing approval for daridorexant in South Korea, License agreement for a GPCR-targeting program with a European venture company and acquisition of shares in that company, Changes to the directors, Obtained marketing approval for QUVIVIQ in Taiwan, with a launch planned during 2026 |
Items this document does not state (21)
Gross Profit MarginOperating profit marginFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The primary factor was the achievement of 7 milestones in the first quarter, compared with 1 milestone in the same period of the previous year. Research and development expenses decreased due to lower costs as multiple clinical development programs progressed and a more focused approach to research and development areas. Selling, general and administrative expenses decreased as a result of cost-cutting initiatives.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.